BofA Finance LLC has filed a new offering of Auto-Callable Notes totaling $1.727 million, guaranteed by Bank of America Corporation. This filing, dated October 30, 2026, is significant as it reflects the company’s strategy to enhance its financial product offerings in a competitive banking landscape.
The offering is structured to be linked to the performance of major stock indices, including the Nasdaq-100, Russell 2000, and S&P 500. This approach indicates a shift towards performance-based investment solutions that could appeal to a broad range of investors.
Background
BofA Finance LLC operates under the SIC classification of National Commercial Banks (6021). The company is incorporated in Delaware and has its business address at 100 North Tryon Street, Charlotte, North Carolina. BofA Finance is a subsidiary of Bank of America Corporation, which is also classified under the same SIC category. Recent filings indicate a series of offerings on the same date, showcasing an active strategy in the capital markets.
What the Filing Says
The filing states, "Auto-Callable Notes Linked to the Least Performing of the Nasdaq-100 Index, the Russell 2000 Index and the S&P 500 Index, due October 31, 2031, priced on October 28, 2026, and will issue on November 2, 2026." This highlights the notes' structure and the performance metrics tied to well-known indices.
Impact
This offering may affect a variety of stakeholders, including potential investors looking for innovative investment products linked to market performance. Additionally, it positions BofA Finance LLC competitively among other national commercial banks, which may prompt similar offerings from competitors seeking to attract investor interest.
What's Next
The filing does not say what happens next.
Read Next
BP Sells 5% Stake in Aker BP for $1.06 Billion
WeRide Inc. Reports Stability in Share Capital Movements
Bullish Releases October 2026 Monthly Metrics Report
Chimera Investment Corp declares cash dividends for Q4 2026
Modern Mining Technology registers common shares on NYSE American
Innate Pharma Reports Q3 2026 Update, Highlights Pipeline Progress










